argenex (NASDAQ:ARGX – Get Free Report) had its price objective increased by Robert W. Baird from $823.00 to $861.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Robert W. Baird‘s target price would suggest a potential downside of 1.69% from the stock’s previous close.
Several other research firms have also weighed in on ARGX. Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Jefferies Financial Group reiterated a “buy” rating on shares of argenex in a research report on Monday, September 14th. Oppenheimer cut their price target on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a report on Monday, October 12th. Piper Sandler boosted their price target on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of argenex in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,150.00.
View Our Latest Research Report on argenex
argenex Price Performance
Shares of NASDAQ:ARGX opened at $875.76 on Friday. The business’s fifty day moving average price is $956.17 and its two-hundred day moving average price is $885.45. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The stock has a market capitalization of $55.08 billion, a price-to-earnings ratio of 33.63, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44.
argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a return on equity of 43.59% and a net margin of 32.19%. Research analysts expect that argenex will post 28.71 EPS for the current fiscal year.
Hedge Funds Weigh In On argenex
Institutional investors and hedge funds have recently bought and sold shares of the business. WPG Advisers LLC boosted its stake in argenex by 17.8% in the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares in the last quarter. Mather Group LLC. increased its stake in shares of argenex by 19.1% in the third quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after buying an additional 13 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of argenex by 3.6% in the third quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock valued at $363,000 after buying an additional 13 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of argenex by 2.8% in the first quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after buying an additional 14 shares in the last quarter. Finally, Nvwm LLC raised its holdings in shares of argenex by 1.3% in the third quarter. Nvwm LLC now owns 1,538 shares of the company’s stock valued at $1,475,000 after buying an additional 20 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.
About argenex
argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.
argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.
Further Reading
- Five stocks we like better than argenex
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
